Amgen’s Lumakras targets a mutation called KRAS that is common among many cancers

Please feel free to read, share your thoughts, your stories and connect with others!
User avatar
GrouseMan
Posts: 888
Joined: Mon Aug 12, 2013 12:30 pm
Location: SE Michigan USA

Re: Amgen’s Lumakras targets a mutation called KRAS that is common among many cancers

Postby GrouseMan » Mon Sep 12, 2022 6:08 pm

This is a small molecule inhibitor of the KRAS G12C mutated protein. Used for some people that have this particular mutation in Small Cell Lung Cancer. 30 to 50% of Colon cancers have KRAS Mutations and only a small percentage of those (3 to 4%) are of the G12C variety. In Small Cell Lung Cancer up to 40% of the people with KRAS mutations are of the G12C variety, but only about 30% of people with Lung Cancer have KRAS Mutants. It's not likely that LUMAKRAS will have a big impact on Colon Cancer treatment. Most likely only for a very few people that have been tested and been found to harbor that particular mutation. But the market is much better for those with Lung Cancer.

GrouseMan
DW 53 dx Jun 2013
CT mets Liver Spleen lung. IVb CEA~110
Jul 2013 Sig Resct
8/13 FolFox,Avastin 12Tx mild sfx, Ongoing 5-FU Avastin every 3 wks.
CEA: good marker
7/7/14 CT Can't see the spleen Mets.
8/16/15 CEA Up, CT new abdominal mets. Iri, 5-FU, Avastin every 2 wks.
1/16 Iri, Erbitux and likely Avastin (Trial) CEA going >.
1/17 CEA up again dropped from Trial, Mets growth 4-6 mm in abdomen
5/2/17 Failed second trial, Hospitalized 15 days 5/11. Home Hospice 5/26, at peace 6/4/2017

Return to “Colon Talk - Colon cancer (colorectal cancer) support forum”



Who is online

Users browsing this forum: No registered users and 132 guests